Immunogen Return on Equity

Immunogen (IMGN) currently reports a ROE of -13.01%. That is above the Healthcare sector average of -100.59%. Use the charts on this page to explore Immunogen's ROE history and peer comparisons.

Immunogen's ROE of -13.01% is higher than the Healthcare sector average of -100.59%. That is roughly 87.1% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Immunogen's current -13.01% should be judged against Healthcare norms (sector average: -100.59%) and against IMGN's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of -13.01%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is -100.59%. From there, open related valuation or income-statement pages for Immunogen, and consider following IMGN for alerts when major investors trade the stock.

Immunogen is classified in the Healthcare sector. On ROE, it currently shows -13.01% versus a sector average near -100.59%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing IMGN with unrelated industries.